Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Daratumumab in myeloma update: expanding indications

Niels van de Donk • 5 Oct 2018
ESH MM 2018
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Melphalan Pomalidomide Prednisolone
ALCYONE APOLLO

Daratumumab has been a success in the treatment of multiple myeloma (MM), both as a monotherapy and in combination regimens. However, its success doesn’t end there; new indications and combinations are being explored for the antibody in MM, as well as a subcutaneous formulation to greatly improve treatment time and convenience. Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses these at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

More from Niels van de Donk

4:33
Cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
Niels van de Donk • 13 Dec 2021
2:42
Iberdomide plus dexamethasone for heavily pretreated multiple myeloma
Niels van de Donk • 13 Dec 2021
3:03
The future of CAR-T therapy for multiple myeloma
Niels van de Donk • 13 Dec 2021
1:45
Mechanisms of action of CD38 antibodies in myeloma
Niels van de Donk • 13 Dec 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals